The global recombinant veterinary vaccine market is on a robust growth trajectory, projected to increase from USD 1.37 billion in 2024 to USD 2.39 billion by 2032, registering a CAGR of 7.22%. This upward trend is fundamentally powered by the superior safety, efficacy, and targeted protection that recombinant technology offers over conventional vaccine methods. https://www.databridgemarketresearch.com/reports/global-recombinant-veterinary-vaccine-market